Author: Florian Stieglitz, Consultant, Market Access

Germany’s draft contribution rate stabilization law for the statutory health insurance system (GKV-Beitragssatzstabilisierungsgesetz) has passed the next political hurdle: the bill was approved by the Federal Cabinet on 29 April and has now entered the parliamentary process. The first reading is expected around 11 June, with second and third readings currently scheduled for 26 June. 

Compared with the original draft, which we covered previously, many core elements remain unchanged. At the same time, some important adjustments have been made that could materially affect price negotiations, launch strategy, and long-term market access planning. 

What remains unchanged 

1. Abolition of the guardrails and the combination discount remains in place 

The Cabinet draft confirms that both the AMNOG guardrails and the combination discount for patented medicines are to be abolished. 

Strategic implications 

For products currently affected by the combination discount, this is clearly positive news: these medicines may once again be able to generate higher revenues in the future. 

The reconfirmed abolition of the guardrails is particularly relevant for ongoing or upcoming price negotiations. Companies should use this as a meaningful lever to strengthen their negotiation position. 

If a product has demonstrated only a minor or non-quantifiable additional benefit compared with a patent or document protected appropriate comparator therapy (ACT), annual treatment costs may again exceed those of the ACT and are no longer automatically capped at the comparator level. Likewise, if a product has shown no additional benefit versus a patent-protected ACT, annual treatment costs no longer have to be set at least 10% below the comparator; instead, they are capped at the ACT cost level. 

In practice, this restores flexibility in negotiations and may improve the pricing outlook for selected products. 

2. The revised arbitration fallback for price-volume regulation remains unchanged 

If no agreement on the price volume model is reached in price negotiations, the revised arbitration model remains the fallback option with a caped discount of 1.7% depending on the sales growth and additionally a 1% discount must be granted for every EUR 100 million in sales growth compared with the reference year, instead of the previously 0.1% in the original arbitration model. 

Strategic implications 

This is especially relevant for medicines with high revenue potential. For these products, companies should explicitly reflect the fall-back scenario in their negotiation preparation, model multiple revenue trajectories, and test different price-volume constructs to mitigate downside risk. 

For products with lower expected sales, however, the now institutionalized arbitration model may still represent a relatively acceptable fallback option and may even strengthen the company’s negotiation position. 

3. Pilot rebate contracts for patented medicines with therapeutically comparable effectswithinsubstance classes remain in place 

The draft also retains the rule allowing statutory health insurers to conclude rebate contracts for patent-protected medicines with therapeutically comparable effects. Initially, this will apply in a pilot phase until 31 December 2030 and will be limited to five substance classes: 

• JAK inhibitors  

• CGRP antagonists  

• PARP inhibitors  

• PCSK9 inhibitors  

• PD-1/PD-L1 inhibitors  

Importantly, the clustering of products and the assessment of therapeutic equivalence will largely be driven by the health insurers themselves. The G-BA will not define these groups. 

Strategic implications 

This could materially reshape competitive dynamics in selected classes. As soon as multiple products from the same class are approved in the same indication, the negotiated AMNOG price may become less relevant if payer-led clustering and contracting dynamics take hold. 

This makes launch strategy even more critical. Companies may need to consider niche positioning approaches to partially avoid a new competitive logic that increasingly resembles the generics market. Smaller patient populations, or settings in which a substance class is not yet established, could therefore become more attractive from a launch perspective. 

What has changed 

4. Dynamic manufacturer rebateremains,but a possible exemption has been added 

The planned dynamic manufacturer rebate remains part of the draft and is unchanged compared with the earlier version. Under the proposal, the current 7% manufacturer rebate would be supplemented by a dynamic component from July 2027 onward. In addition, a temporary static increase of 3.5 percentage points is foreseen for the period from 1 January to 30 June 2027. 

The rationale remains the same: expenditure growth in the patented medicines market. Going forward, the level of the rebate would depend on the development of GKV revenues and expenditures, making revenues in Germany significantly less predictable and increasing commercial uncertainty. 

What is new, however, is the proposed introduction of a so-called “Germany bonus” — effectively a location-based exemption for medicines with new active substances first launched from 1 January 2027 onward. 

An exemption from the dynamic manufacturer rebate may be granted if: 

• a relevant share of clinical trial activity took place in Germany (5% German study population corresponding to the former medical research act for guard rail exemption), and  

• active substance manufacturing in Germany is expected to make a meaningful contribution to security of supply (Volume of active substance produced is expected to be sufficient to treat at least 50% of eligible patients over a three-year period).  

The Cabinet cover note also states that the parliamentary process will examine whether these criteria should remain cumulative or instead become alternative conditions. 

Strategic implications 

The dynamic rebate itself continues to increase uncertainty around German revenues and will make forecasting, launch planning, and business case modelling more difficult, particularly for products with significant sales potential. 

At the same time, the newly introduced exemption creates an important strategic lever. If the final law moves toward an either/or structure, companies without a German manufacturing footprint may still be able to secure exemption through deliberate clinical development planning with meaningful German trial participation. 

This would make market access involvement in study planning and development strategy more important than ever. For companies seeking stable and predictable revenues in Germany, still the most important pharmaceutical market in the European Union, early alignment between clinical development, manufacturing footprint, and market access strategy could become a decisive success factor.  

What happens next 

As the well-known “Struck’s law” reminds us: no bill leaves the German Bundestag in the same form in which it entered. 

That means the parliamentary process remains highly relevant, and additional changes are still possible. For now, however, the direction of travel is clear: the proposed legislation would further increase pricing pressure and market complexity in Germany, while also creating new strategic levers for companies that prepare early and position themselves carefully. 

Germany’s savings law is becoming more concrete and with it, the next phase of AMNOG evolution. For pharma companies, the message is clear: pressure is rising, predictability is falling, and strategic preparation is becoming more important than ever.